$150.20
0.81% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US5011471027
Symbol
KRYS

Krystal Biotech, Inc. Stock price

$150.20
+15.26 11.31% 1M
-21.63 12.59% 6M
-6.46 4.12% YTD
-36.58 19.58% 1Y
+79.48 112.39% 3Y
+105.76 237.98% 5Y
+139.56 1,311.65% 10Y
+139.56 1,311.65% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+1.20 0.81%

Key metrics

Basic
Market capitalization
$4.3b
Enterprise Value
$3.7b
Net debt
positive
Cash
$682.0m
Shares outstanding
28.9m
Valuation (TTM | estimate)
P/E
30.6 | 29.7
P/S
12.1 | 11.1
EV/Sales
10.2 | 9.4
EV/FCF
19.8
P/B
4.2
Financial Health
Equity Ratio
89.6%
Return on Equity
9.4%
ROCE
14.4%
ROIC
30.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$359.2m | $390.3m
EBITDA
$158.1m | $153.6m
EBIT
$151.8m | $148.3m
Net Income
$146.7m | $146.4m
Free Cash Flow
$185.4m
Growth (TTM | estimate)
Revenue
116.1% | 34.3%
EBITDA
1,346.1% | 39.8%
EBIT
3,666.7% | 43.7%
Net Income
38.5% | 64.2%
Free Cash Flow
915.1%
Margin (TTM | estimate)
Gross
93.4%
EBITDA
44.0% | 39.4%
EBIT
42.3%
Net
40.9% | 37.5%
Free Cash Flow
51.6%
More
EPS
$4.9
FCF per Share
$6.4
Short interest
20.2%
Employees
275
Rev per Employee
$1.1m
Show more

Is Krystal Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Krystal Biotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Krystal Biotech, Inc. forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Krystal Biotech, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Krystal Biotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
359 359
116% 116%
100%
- Direct Costs 24 24
107% 107%
7%
335 335
117% 117%
93%
- Selling and Administrative Expenses 128 128
25% 25%
36%
- Research and Development Expense 56 56
15% 15%
16%
158 158
1,346% 1,346%
44%
- Depreciation and Amortization 6.26 6.26
9% 9%
2%
EBIT (Operating Income) EBIT 152 152
3,667% 3,667%
42%
Net Profit 147 147
39% 39%
41%

In millions USD.

Don't miss a Thing! We will send you all news about Krystal Biotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Krystal Biotech, Inc. Stock News

Positive
Seeking Alpha
13 days ago
I maintain a Strong Buy on Krystal Biotech, as the pause in melanoma trial enrollment is offset by promising progress in inhaled KB707 for NSCLC. Inhaled KB707 achieved a 36% ORR in heavily pretreated NSCLC patients, and an FDA end-of-Phase-2 meeting is scheduled for October 2025. Strong revenue growth from VYJUVEK and international launches, plus a robust pipeline, support long-term value desp...
Neutral
GlobeNewsWire
14 days ago
PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, the Company's redosable immunotherapy designed to drive sustained, localized expression of interleukin-2 (IL-2) and interleukin-12 (IL-12) in the tumor microenvironment and promote systemic immune-...
Neutral
Seeking Alpha
about one month ago
Krystal Biotech, Inc. (NASDAQ:KRYS ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Kathryn A. Romano - Executive VP & Chief Accounting Officer Krish S.
More Krystal Biotech, Inc. News

Company Profile

Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Head office United States
CEO Krish Krishnan
Employees 275
Founded 2016
Website www.krystalbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today